(Measles [strain Enders Edmonston] + mumps [strain Jeryl Lynn (Level B)] + rubella [strain Wistar RA 27/3] + varicella [strain Oka/Merck]) vaccine is a Live Attenuated Vaccine owned by Merck & Co, and is involved in 13 clinical trials, which were completed.

ProQuad works by teaching the immune system (the body’s natural defences) how to defend itself against a disease. ProQuad contains small amounts of weakened forms of the viruses that cause measles, mumps, rubella, and chickenpox. When a person is given the vaccine, the immune system recognizes the weakened viruses as foreign and makes antibodies against them. In the future, the immune system will be able to produce antibodies quicker when it is again exposed to the viruses. The antibodies will help to protect against diseases caused by these viruses.

The revenue for (Measles [strain Enders Edmonston] + mumps [strain Jeryl Lynn (Level B)] + rubella [strain Wistar RA 27/3] + varicella [strain Oka/Merck]) vaccine is expected to reach a total of $48.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Measles [strain Enders Edmonston] + mumps [strain Jeryl Lynn (Level B)] + rubella [strain Wistar RA 27/3] + varicella [strain Oka/Merck]) vaccine NPV Report.

(Measles [strain Enders Edmonston] + mumps [strain Jeryl Lynn (Level B)] + rubella [strain Wistar RA 27/3] + varicella [strain Oka/Merck]) vaccine is currently owned by Merck & Co.

(Measles [strain Enders Edmonston] + mumps [strain Jeryl Lynn (Level B)] + rubella [strain Wistar RA 27/3] + varicella [strain Oka/Merck]) vaccine Overview

Measles [strain Enders Edmonston], Mumps [strain Jeryl Lynn (Level B)], Rubella [strain Wistar RA 27/3] and Varicella [strain Oka/Merck]) vaccine (ProQuad) is an acrive immunizing preparation containing the components of M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live), a more attenuated line of measles virus, derived from Enders attenuated Edmonston strain and propagated in chick embryo cell culture; Mumps Virus Vaccine Live, the Jeryl Lynn (B level) strain of mumps virus propagated in chick embryo cell culture; Rubella Virus Vaccine Live, the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblast and  Varicella Virus Vaccine Live (Oka/Merck), the Oka/Merck strain of varicella-zoster virus propagated in MRC-5 cells. It is formulated as lyophilized powder for suspension for subcutaneous or intramuscular route of administration. ProQuad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.

Merck & Co Overview

Merck & Co (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

The company reported revenues of (US Dollars) US$48,704 million for the fiscal year ended December 2021 (FY2021), an increase of 17.3% over FY2020. In FY2021, the company’s operating margin was 25.7%, compared to an operating margin of 12% in FY2020. In FY2021, the company recorded a net margin of 26.8%, compared to a net margin of 17% in FY2020. The company reported revenues of US$14,959 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.

Quick View – (Measles [strain Enders Edmonston] + mumps [strain Jeryl Lynn (Level B)] + rubella [strain Wistar RA 27/3] + varicella [strain Oka/Merck]) vaccine

Report Segments
  • Innovator (NME)
Drug Name
  • (Measles [strain Enders Edmonston] + mumps [strain Jeryl Lynn (Level B)] + rubella [strain Wistar RA 27/3] + varicella [strain Oka/Merck]) vaccine
Administration Pathway
  • Intramuscular
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
Key Companies
  • Sponsor Company: Merck & Co
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.